S-1: GT Biopharma Seeks to Raise Capital Through Public Offering of Common Stock and Warrants

GT Biopharma is conducting a public offering of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Summary

• GT Biopharma is undertaking a public offering to sell shares of its common stock along with common warrants to purchase additional shares.
• The offering also includes pre-funded warrants for purchasers who would exceed a certain ownership threshold (4.99% or 9.99%) if they bought common stock directly.
• Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.0001 per share.
• The company has engaged Roth Capital Partners, LLC as the exclusive placement agent for the offering.
• The offering has no minimum number of shares or proceeds required to close.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of its product candidates.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol GTBP.
• As of December 20, 2024, the last reported sale price of GTBP was $1.75 per share.
• The offering will terminate no later than , 2025, unless the company decides to terminate the offering prior to that date.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the company's efforts to raise capital and advance its clinical programs, it also acknowledges significant risks and uncertainties, including the company's financial condition and the competitive landscape.

Positives

• The offering aims to provide GT Biopharma with additional capital to advance its clinical programs and for general corporate purposes.
• The inclusion of pre-funded warrants allows for flexibility in accommodating investors who may have ownership limitations.
• The company has already advanced GTB-3650 through requisite preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in December 2023.
• In late June 2024, the FDA cleared our IND Application for GTB-3650.
• We expect to start study enrollment targeting patients with relapsed/refractory AML and high grade MDS early in the first quarter of 2025.

Negatives

• The offering has no minimum amount of proceeds required to close, which may result in the company receiving less capital than anticipated.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• Investing in the company's securities involves a high degree of risk.
• The company has a history of operating losses and expects to continue to incur losses for the foreseeable future.
• The company will need additional capital to conduct its operations and develop its products, and its ability to obtain the necessary funding is uncertain.
• The company's failure to maintain compliance with the Nasdaq Capital Markets (Nasdaq) continued listing requirements could result in the delisting of its common stock.

Risks

• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• The company may not develop therapeutic products that can be commercialized.
• The company has a history of operating losses and may never generate revenue or achieve profitability.
• The company will need additional capital to conduct its operations and develop its products, and its ability to obtain the necessary funding is uncertain.
• The cost of the company's research and development programs may be significantly higher than expected.
• The company's failure to maintain compliance with the Nasdaq Capital Markets (Nasdaq) continued listing requirements could result in the delisting of its common stock.
• There has been a limited public market for the company's common stock, and the trading price for its common stock may be volatile and could be subject to wide fluctuations in per-share price.
• Purchasers of the company's common stock in this offering will experience immediate and substantial dilution in the book value of their investment.
• The company's management will have broad discretion as to the use of the proceeds from this offering, and may not use the proceeds effectively.
• There is no public market for the common warrants or pre-funded warrants being offered by the company in this offering.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of its product candidates that are currently undergoing clinical trials, its product candidates that it expects to submit an investigational new drug application for in the near term, and its product candidates that are pre-clinical.

Industry Context

GT Biopharma is operating in the competitive immuno-oncology space, focusing on novel therapies using its TriKE and Dual Targeting TriKE platforms. The company is targeting hematologic malignancies and solid tumors, areas with significant unmet medical needs and substantial market potential.

Comparison to Industry Standards

• The document does not contain enough information to make a comparison to industry standards.

Stakeholder Impact

• Shareholders may experience dilution as a result of the public offering.
• Employees may be affected by the company's ability to secure funding and continue operations.
• The company's success in developing and commercializing its product candidates could benefit patients with hematologic malignancies and solid tumors.
• The company's suppliers and creditors may be affected by its financial condition and ability to meet its obligations.

Next Steps

• The company will proceed with the public offering, seeking to raise capital.
• The company intends to submit to Nasdaq, within the requisite time period, a plan to regain compliance with Listing Rule 5550(b)(1).
• The company expects to start study enrollment targeting patients with relapsed/refractory AML and high grade MDS early in the first quarter of 2025.
• The company will continue to develop its product candidates and pursue regulatory approvals.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, GT Biopharma, Roth Capital Partners, capital raise, GTBP, immuno-oncology, TriKE, clinical trials, FDA